House Rx Raises $55M to Scale In-Clinic Specialty Pharmacy Network

House Rx, a health technology company focused on improving access to specialty medications, has secured $55 million in Series B equity and debt funding. The round was led by New Enterprise Associates (NEA) and Town Hall Ventures, with participation from LRVHealth, First Round Capital, Bessemer Venture Partners, and Silicon Valley Bank. The company’s total capital raised now stands at $100 million.

Founded in 2021, House Rx is redefining specialty pharmacy by enabling clinics to dispense specialty medications directly to their patients through a medically integrated and technology-driven model. The company’s platform combines pharmacist expertise with modern software, promoting real-time collaboration between physicians and pharmacists to enhance care coordination, reduce administrative complexity, and improve outcomes for patients managing complex diseases.

“There’s finally momentum behind building a specialty pharmacy ecosystem that makes it easier and more affordable for patients to access the medications they need,” said Ogi Kavazovic, CEO and Founder of House Rx. “We’re seeing enthusiasm from providers, manufacturers, payers, investors, and employees who recognize the chance to challenge the status quo—improving care for patients while tackling unsustainable costs. With new funding, we’re ready to scale rapidly to meet this growing demand.”

House Rx’s approach offers a decentralized alternative to the traditional Pharmacy Benefit Manager (PBM)-owned, closed-network specialty pharmacies that have drawn regulatory scrutiny. The company’s network of clinic-embedded dispensaries emphasizes patient-centered care by integrating pharmacy operations within specialty clinics. This model reduces fulfillment fragmentation and administrative friction, fostering direct engagement between care teams and patients.

Currently, House Rx partners with over 1,000 providers across 80 clinic sites nationwide, processing approximately $1.5 billion in specialty prescriptions annually—a figure projected to double by 2026. The company’s proprietary pharmacy management platform powers this growth, supporting operational efficiency and scalability. In April, House Rx launched Smart PA, an AI-based feature that automates 80% of prior authorizations, significantly streamlining administrative workflows. Additional AI capabilities are under development to further embed automation and efficiency within the House Rx system.

With strong investor backing and growing adoption, House Rx is positioning itself as a scalable infrastructure provider for the next generation of integrated, locally operated specialty pharmacy care.

Click here for the original news story.